Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing`s Disease

Study:

An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing`s Disease (Seascape)

Rationale:

n/a

Purpose:

This study will document the safety and efficacy of pasireotide s.c. in patients with Cushing`s disease.

Study Status: Recruiting

Recruiting:
n/a

Condition Intervention Phase
Cushing`s Disease Drug: Pasireotide sub-cutaneous formulation Phase 3

Verified by Novartis Pharmaceuticals December, 2013

Sponsored by: Novartis Pharmaceuticals
Information provided by: Novartis
ClinicalTrials.gov identifier: NCT01582061

Study Type: Interventional

Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Novartis Pharmaceuticals., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site